Micro-CT imaging analysis for the effect of celecoxib, a cyclooxygenase-2 inhibitor, on inflammatory bone destruction in adjuvant arthritis rats

Journal of Bone and Mineral Metabolism

Volumn 26, Issue 5, 2008, Pages 461-468

  Noguchi, Masahiro ^a   Kimoto, Aishi ^a   Sasamata, Masao ^a   Miyata, Keiji ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Adjuvant induced arthritis; Cyclooxygenase; Micro computed tomography; Nonsteroidal antiinflammatory drugs; Trabecular microarchitecture

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; LIQUID PARAFFIN; LOXOPROFEN; SC 58560; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; BONE EROSION; BONE STRUCTURE; CALCANEUS; CONTROLLED STUDY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FOOT PAD; INFLAMMATION; MALE; MICRO-COMPUTED TOMOGRAPHY; MYCOBACTERIUM BUTYRICUM; NONHUMAN; PRIORITY JOURNAL; RAT; TRABECULAR BONE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; BONE DISEASES; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INFLAMMATION; MALE; ORGANIC CHEMICALS; PHENYLPROPIONATES; PYRAZOLES; RATS; RATS, INBRED LEW; SULFONAMIDES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 50949097032     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-008-0855-3     Document Type: Article

References (44)

1. E.M. Gravallese 2002 Bone destruction in arthritis Ann Rheum Dis 61 suppl2 ii84 ii86
2. N.C. Walsh E.M. Gravallese 2004 Bone loss in inflammatory arthritis: mechanisms and treatment strategies Curr Opin Rheumatol 16 419 427
3. W.L. Smith D.L. Dewitt 1996 Prostaglandin endoperoxide H synthases-1 and-2 Adv Immunol 62 167 215
4. J.R. Vane Y.S. Bakhle R.M. Botting 1998 Cyclooxygenases 1 and 2 Annu Rev Pharmacol Toxicol 38 97 120
5. R.Y. Kang J. Freire-Moar E. Sigal C.Q. Chu 1996 Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis Br J Rheumatol 35 711 718
6. G.D. Anderson S.D. Hauser K.L. McGarity M.E. Bremer P.C. Isakson S.A. Gregory 1996 Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis J Clin Invest 97 2672 2679
7. J. Angel F. Berenbaum C. Le Denmat T. Nevalainen J. Masliah C. Fournier 1994 Interleukin-1-induced prostaglandin E2 biosynthesis in human synovial cells involves the activation of cytosolic phospholipase A2 and cyclooxygenase-2 Eur J Biochem 226 125 131
8. A. Szczepanski T. Moatter W.W. Carley M.E. Gerritsen 1994 Induction of cyclooxygenase II in human synovial microvessel endothelial cells by interleukin-1. Inhibition by glucocorticoids Arthritis Rheum 37 495 503
9. H. Tai C. Miyaura C.C. Pilbeam T. Tamura Y. Ohsugi Y. Koishihara N. Kubodera H. Kawaguchi L.G. Raisz T. Suda 1997 Transcriptional induction of cyclooxygenase-2 in osteoblasts is involved in interleukin-6-induced osteoclast formation Endocrinology 138 2372 2379
10. T. Mino U. Yuasa F. Nakamura M. Naka T. Tanaka 1998 Two distinct actin-binding sites of smooth muscle calponin Eur J Biochem 251 262 268
11. Y. Sakuma K. Tanaka M. Suda Y. Komatsu A. Yasoda M. Miura A. Ozasa S. Narumiya Y. Sugimoto A. Ichikawa F. Ushikubi K. Nakao 2000 Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype Infect Immun 68 6819 6825
12. Y. Okada J.A. Lorenzo A.M. Freeman M. Tomita S.G. Morham L.G. Raisz C.C. Pilbeam 2000 Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture J Clin Invest 105 823 832
13. C.E. Trebino J.L. Stock C.P. Gibbons B.M. Naiman T.S. Wachtmann J.P. Umland K. Pandher J.M. Lapointe S. Saha M.L. Roach D. Carter N.A. Thomas B.A. Durtschi J.D. McNeish J.E. Hambor P.J. Jakobsson T.J. Carty J.R. Perez L.P. Audoly 2003 Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase Proc Natl Acad Sci U S A 100 9044 9049
14. 2-mediated bone resorption associated with inflammation J Exp Med 197 1303 1310
15. T. Suzawa C. Miyaura M. Inada T. Maruyama Y. Sugimoto F. Ushikubi A. Ichikawa S. Narumiya T. Suda 2000 The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs Endocrinology 141 1554 1559
16. X. Li Y. Okada C.C. Pilbeam J.A. Lorenzo C.R. Kennedy R.M. Breyer L.G. Raisz 2001 Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro Endocrinology 141 2054 2061
17. 2 induced the differentiation of osteoclasts in mouse osteoblast-depleted bone marrow cells Prostaglandins Leukot Essent Fatty Acids 68 351 358
18. X.H. Liu A. Kirschenbaum S. Yao A.C. Levine 2006 Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system Endocrinology 1068 225 233
19. W.S. Simonet D.L. Lacey C.R. Dunstan M. Kelley M.S. Chang 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 309 319
20. E.A. O'Brien J.H. Williams M.J. Marshall 2001 Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane Bone (NY) 28 208 214
21. K. Suda N. Udagawa N. Sato M. Takami K. Itoh J.T. Woo N. Takahashi K. Nagai 2004 Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharideinduced osteoclast formation J Immunol 172 2504 2510
22. S.L. Morgan D.T. Chen J. Carlee J.E. Baggott 2004 Effect of methotrexate therapy on bone mineral density and body composition in rat adjuvant arthritis J Rheumatol 31 1693 1697
23. A.M. Badger S. Blake R. Kapadia S. Sarkar J. Levin B.A. Swift S.J. Hoffman G.B. Stroup W.H. Miller M. Gowen M.W. Lark 2001 Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvantinduced arthritis Arthritis Rheum 44 128 137
24. C.M. Pearson 1956 Development of arthritis, periarthritis and periostitis in rats given adjuvant Proc Soc Exp Biol Med 91 95 101
25. C.M. Pearson F.D. Wood 1959 Studies of polyarthritis and other lesions induced in rats by injection of mycobacterial adjuvant: I. General clinical and pathologic characteristics and some modifying factors Arthritis Rheum 2 440 459
26. C.J. Smith Y. Zhang C.M. Koboldt J. Muhammad B.S. Zweifel A. Shaffer J.J. Talley J.L. Masferrer K. Seibert P.C. Isakson 1998 Pharmacological analysis of cyclooxygenase-1 in inflammation Proc Natl Acad Sci U S A 95 13313 13318
27. M. Noguchi A. Kimoto J.K. Gierse M.C. Walker B.S. Zweifel K. Nozaki M. Sasamata 2005 Enzymologic and pharmacologic profile of loxoprofen sodium and its metabolites Biol Pharm Bull 28 2075 2079
28. J.L. Masferrer B.S. Zweifel P.T. Manning S.D. Hauser K.M. Leahy W.G. Smith P.C. Isakson K. Seibert 1994 Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic Proc Natl Acad Sci U S A 91 3228 3232
29. J.K. Gierse Y. Zhang W.F. Hood M.C. Walker J.S. Trigg T.J. Maziasz C.M. Koboldt J.L. Muhammad B.S. Zweifel J.L. Masferrer P.C. Isakson K. Seibert 2005 Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity J Pharmacol Exp Ther 312 1206 1212
30. M. Noguchi A. Kimoto S. Kobayashi T. Yoshino K. Miyata M. Sasamata 2005 Effect of celecoxib, a cyclooxygenase-2 inhibitor, on the pathophysiology of adjuvant arthritis in rat Eur J Pharmacol 513 229 235
31. M. Ito A. Nishida A. Koga S. Ikeda A. Shiraishi M. Uetani K. Hayashi T. Nakamura 2002 Contribution of trabecular and cortical components to the mechanical properties of bone and their regulating parameters Bone (NY) 31 351 358
32. M. Hahn M. Vogel M. Pompesius-Kempa G. Delling 1992 Trabecular bone pattern factor: a new parameter for simple quantification of bone microarchitecture Bone (NY) 13 327 330
33. M. Ito K. Ikeda M. Nishiguchi H. Shindo M. Uetani T. Hosoi H. Orimo 2005 Multi-detector row CT imaging of vertebral microstructure for evaluation of fracture risk J Bone Miner Res 20 1828 1836
34. M. Bonde P. Garnero C. Fledelius P. Qvist P.D. Delmas C. Christiansen 1996 Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen J Bone Miner Res 12 1028 1034
35. V. Breuil F. Cosman L. Stein W. Horbert J. Nieves V. Shen R. Lindsav D.W. Dampster 1998 Human osteoclast formation and activity in vitro: effects of alendronate J Bone Miner Res 13 1721 1729
36. C. Rosenquist C. Fledelius S. Christgau B.J. Pedersen M. Bonde P. Qvist C. Christiansen 1998 Serum CrossLaps One Step ELISA First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 44 2281 2289
37. F. Abbate A. Casini A. Scozzafava C.T. Supuran 2004 Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with a topically acting antiglaucoma sulfonamide Bioorg Med Chem Lett 14 2357 2361
38. A. Weber A. Casini A. Heine D. Kuhn C.T. Supuran A. Scozzafava G. Klebe 2004 Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition J Med Chem 47 550 557
39. M. Katagiri T. Ogasawara K. Hoshi D. Chikazu A. Kimoto M. Noguchi M. Sasamata S. Harada H. Akama H. Tazaki U.I. Chung T. Takato K. Nakamura H. Kawaguchi 2006 Suppression of adjuvantinduced arthritic bone destruction by cyclooxygenase-2 selective agents with and without inhibitory potency against carbonic anhydrase II J Bone Miner Res 21 219 227
40. N. Kusunoki R. Yamazaki S. Kawai 2002 Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors Arthritis Rheum 46 3159 3167
41. T. Sugatani K.A. Hruska 2005 Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors J Biol Chem 280 3583 3589
42. A.L. Hsu T.T. Ching D.S. Wang X. Song V.M. Rangnekar C.S. Chen 2000 The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2 J Biol Chem 275 11397 11403
43. H. El Hajjaji A. Marcelis J.P. Devogelaer D.H. Manicourt 2003 Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage J Rheumatol 30 2444 2451
44. S.C. Mastbergen N.W. Jansen J.W. Bijlsma F.P. Lafeber 2006 Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study Arthritis Res Ther 8 R2